Aeterna Zentaris Inc. (AEZS) (AEZS.TO) is all set to announce top-line results from its phase III study of Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer prior to the commencement of trading on Monday, May 1, 2017.
The phase III study, dubbed ZoptEC, enrolled over 500 patients, who were centrally randomized in a 1:1 ratio and received either Zoptrex or chemotherapy medication Doxorubicin intravenously, every three weeks and for up to nine cycles.
Response was evaluated every three cycles during treatment, and thereafter, every 12 weeks until progression. All patients were followed for survival as the primary efficacy endpoint. Secondary endpoints include progression-free survival, objective response-rate, and clinical benefit rate.
AEZS closed Friday’s trading at $3.35, up 9.84%.
Galapagos N.V (GLPG) presented pre-clinical data of GLPG1972, a first-in-class small molecule, for the treatment of osteoarthritis, which demonstrated cartilage protection in both rodent and human explant assays.
GLPG1972 is a potent and highly selective inhibitor of ADAMTS-5, a key enzyme involved in cartilage breakdown.
The Company plans to initiate a phase 1b study of GLPG1972 in osteoarthritis patients in the United States this quarter.
GLPG closed Friday’s trading at $86.86, up 1.01%.
Merus B.V. (MRUS) has a couple of catalysts to watch out for in the coming months.
The Company is expected to submit an Investigational New Drug application for MCLA-117 to the FDA and initiate a phase I trial in patients with acute myeloid leukemia during the second half of 2017.
Top line data from part 2 of phase 1/2 monotherapy trial of MCLA-128 in patients with solid tumors in multiple indications are expected during the second half of 2017.
Interim results from Phase 1 clinical trial evaluating MCLA-117 in patients with acute myeloid leukemia are expected to be reported during the second half of 2017.
By the end of 2017, Merus expects to file a CTA for a planned Phase…